公开(公告)号：EP1838710B1

公开(公告)日：2009-07-01

申请号：EP06718361.6

申请日：2006-01-13

申请人： Signal Pharmaceuticals LLC ,  Pharmacopeia, LLC

发明人： ALBERS, Ronald ,  AYALA, Leticia ,  CLAREEN, Steven, S. ,  DELGADO MEDEROS, Maria, M. ,  HILGRAF, Robert ,  HEDGE, Sayee ,  HUGHES, Kevin ,  KOIS, Adam ,  PLANTEVIN-KRENITSKY, Veronique ,  MCCARRICK, Meg ,  NADOLNY, Lisa ,  PALANKI, Moorthy ,  SAHASRABUDHE, Kiran ,  SAPIENZA, John ,  SATOH, Yoshitaka ,  SLOSS, Marian ,  SUDBECK, Elise ,  WRIGHT, Jonathan ,  COLE, Andrew G. ,  HENDERSON, Ian

IPC分类号： C07D473/00 ,  C07D473/32 ,  A61K31/52 ,  A61P3/00 ,  A61P9/00

CPC分类号： C07D473/00 ,  A61K31/52 ,  C07D473/32

摘要： Provided herein are Aminopurine Compounds having the following structure: (I) wherein R1 , R2 and and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

公开(公告)号：EP4328223A3

公开(公告)日：2024-11-06

申请号：EP23205984.0

申请日：2012-04-20

申请人： Signal Pharmaceuticals, LLC

发明人： BENNETT, Brydon ,  ELSNER, Jan ,  ERDMAN, Paul ,  HILGRAF, Robert ,  LEBRUN, Laurie Ann ,  MCCARRICK, Meg ,  MOGHADDAM, Mehran ,  NAGY, Mark A. ,  NORRIS, Stephen ,  PAISNER, David A. ,  SLOSS, Marianne ,  ROMANOW, William J. ,  SATOH, Yoshitaka ,  TIKHE, Jayashree ,  YOON, Won Hyung ,  DELGADO, Maria Mercedes

IPC分类号： C07D239/48 ,  C07D405/02 ,  C07D401/12 ,  C07D409/12

摘要： Provided herein is a compound of formula (I)

or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, isotopologue, or prodrug thereof, wherein R 1 and R 2 are as defined herein. Also provided are methods and reaction intermediates for preparing said compound.

公开(公告)号：EP4328223A2

公开(公告)日：2024-02-28

申请号：EP23205984.0

申请日：2012-04-20

申请人： Signal Pharmaceuticals, LLC

发明人： BENNETT, Brydon ,  ELSNER, Jan ,  ERDMAN, Paul ,  HILGRAF, Robert ,  LEBRUN, Laurie Ann ,  MCCARRICK, Meg ,  MOGHADDAM, Mehran ,  NAGY, Mark A. ,  NORRIS, Stephen ,  PAISNER, David A. ,  SLOSS, Marianne ,  ROMANOW, William J. ,  SATOH, Yoshitaka ,  TIKHE, Jayashree ,  YOON, Won Hyung ,  DELGADO, Maria Mercedes

IPC分类号： C07D409/12

摘要： Provided herein is a compound of formula (I)

or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, isotopologue, or prodrug thereof, wherein R 1 and R 2 are as defined herein. Also provided are methods and reaction intermediates for preparing said compound.

公开(公告)号：EP2699553A1

公开(公告)日：2014-02-26

申请号：EP12718524.7

申请日：2012-04-20

申请人： Signal Pharmaceuticals, LLC

发明人： BENNETT, Brydon, L. ,  ELSNER, Jan ,  ERDMAN, Paul ,  HILGRAF, Robert ,  LEBRUN, Laurie, Ann ,  MCCARRICK, Meg ,  MOGHADDAM, Mehran, F. ,  NAGY, Mark, A. ,  NORRIS, Stephen ,  PAISNER, David, A. ,  SLOSS, Marianne ,  ROMANOW, William, J. ,  SATOH, Yoshitaka ,  TIKHE, Jayashree ,  YOON, Won, Hyung ,  DELGADO, Mercedes

IPC分类号： C07D239/48 ,  C07D405/02 ,  C07D401/12 ,  C07D409/12

CPC分类号： C07D239/48 ,  A61K31/505 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12

摘要： Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R
1 , R
2 , R
3, and R
4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.

公开(公告)号：EP2010186B1

公开(公告)日：2012-12-26

申请号：EP07756113.2

申请日：2007-04-25

申请人： Signal Pharmaceuticals LLC

发明人： ALBERS, Ronald, J. ,  AYALA, Leticia ,  CLAREEN, Steven, S. ,  DELGADO MEDEROS, Maria, Mercedes ,  HILGRAF, Robert ,  HEGDE, Sayee,G., c/o Wilson Sonsini Goodrich ... ,  HUGHES, Kevin ,  KOIS, Adam ,  PLANTEVIN-KRENITSKY, Veronique ,  MCCARRICK, Meg ,  NADOLNY, Lisa ,  PALANKI,Moorthy, S.S. ,  SAHASRAMUDHE, Kiran c/o Wilson Sonsini Goodrich ,  SAPIENZA, John ,  SATOH, Yoshitaka ,  SLOSS, Marianne, K. ,  SUDBECK, Elise ,  WRIGHT, Jonathan

IPC分类号： A61K31/52 ,  A61P3/10

CPC分类号： A61K31/52 ,  C07D473/32

公开(公告)号：EP2010186A1

公开(公告)日：2009-01-07

申请号：EP07756113.2

申请日：2007-04-25

申请人： Signal Pharmaceuticals LLC

发明人： ALBERS, Ronald, J. ,  AYALA, Leticia ,  CLAREEN, Steven, S. ,  DELGADO MEDEROS, Maria, Mercedes ,  HILGRAF, Robert ,  HEGDE, Sayee, G. ,  HUGHES, Kevin ,  KOIS, Adam ,  PLANTEVIN-KRENITSKY, Veronique ,  MCCARRICK, Meg ,  NADOLNY, Lisa ,  PALANKI,Moorthy, S.S. ,  SAHASRAMUDHE, Kiran ,  SAPIENZA, John ,  SATOH, Yoshitaka ,  SLOSS, Marianne, K. ,  SUDBECK, Elise ,  WRIGHT, Jonathan

IPC分类号： A61K31/52 ,  A61P3/10

CPC分类号： A61K31/52 ,  C07D473/32

摘要： Provided herein are Aminopurine Compounds having the following structure (I), wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine. Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

摘要翻译： 本文提供具有以下结构（I）的氨嘌呤化合物，其中R 1，R 2和R 3如本文所定义，包含有效量的氨基嘌呤的组合物。 用于治疗或预防癌症，心血管疾病，肾脏疾病，自身免疫病症，炎性病症，黄斑变性，缺血 - 再灌注损伤，疼痛和相关综合征，疾病相关性消耗，石棉相关病症，肺部疾病 高血压或通过抑制JNK途径可治疗或可预防的病症，所述方法包括向有需要的患者施用有效量的氨嘌呤化合物。